← FDA DRUG APPROVALS

FDA ANDA · ANDA076643

CARBILEV

Sponsor: RANBAXY

APPLICATION
ANDA076643
TYPE
ANDA
ORIGINAL APPROVAL
2005-06-10
LATEST ACTION
2005-06-10
ROUTE
ORAL
DOSAGE FORM
TABLET, FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

CARBILEVDiscontinued
CARBIDOPA 25MG, LEVODOPA 250MG · TABLET, FOR SUSPENSION · ORAL
CARBILEVDiscontinued
CARBIDOPA 10MG, LEVODOPA 100MG · TABLET, FOR SUSPENSION · ORAL
CARBILEVDiscontinued
CARBIDOPA 25MG, LEVODOPA 100MG · TABLET, FOR SUSPENSION · ORAL

Approval history

2005-06-10Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →